IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
View Patent ↗The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
1. A method of monitoring the efficacy of intravenous immunoglobulin (IVIG) treatment of multiple sclerosis in a subject, the method comprising the steps of:
(a) contacting a biological sample from the subject treated with IVIG with a reagent that specifically binds to at least one marker selected from the group consisting of TRERF1 (SEQ ID NOs: 1 and 2), C19orf28 (SEQ ID NOs: 3 and 4), CDKN1C (SEQ ID NOs: 5 and 6), SH3BP4 (SEQ ID NOs: 9 and 10), COL3A1 (SEQ ID NOs: 11 and 12), B3GALT2 (SEQ ID NOs: 13 and 14), MTMR7 (SEQ ID NOs: 17 and 18), TMEFF1 (SEQ ID NOs: 19 and 20), NDUFA5 (SEQ ID NOs: 21 and 22), FAT2 (SEQ ID NOs: 23 and 24), LOC51333 (SEQ ID NOs: 27 and 28), NPR3 (SEQ ID NOs: 29 and 30), EGR2 (SEQ ID NOs: 31 and 32), IL11 (SEQ ID NOs: 71 and 72), XCL2 (SEQ ID NOs: 73 and 74), CASP2 (SEQ ID NOs: 77 and 78), KIR2DS1 (SEQ ID NOs: 79 and 80), MAP4K2 (SEQ ID NOs: 81 and 82), CCL13 (SEQ ID NOs: 87 and 88), AFP (SEQ ID NOs: 89 and 90), and CLEC4E (SEQ ID NOs: 91 and 92);
(b) measuring the expression of the marker;
(c) comparing the expression of the marker in the sample from the subject treated with IVIG to the expression of said at least one marker in a baseline sample from the subject obtained at an earlier timepoint; and
(d) determining whether or not the marker is overexpressed or underexpressed in the sample from the subject treated with IVIG as compared to the expression of the marker in the baseline sample; thereby monitoring the efficacy of IVIG treatment of multiple sclerosis in the subject.
2. The method of claim 1 , wherein the multiple sclerosis is relapsing-remitting multiple sclerosis (RRMS).
3. The method of claim 1 , wherein the reagent is a nucleic acid.
4. The method of claim 1 , wherein the reagent is an oligonucleotide.
5. The method of claim 1 , wherein the reagent is an RT PCR primer set.
6. The method of claim 1 , wherein the sample is a blood sample.
7. The method of claim 6 , wherein the blood sample comprises T cells.
8. The method of claim 1 , wherein the sample is cerebrospinal fluid.
9. The method of claim 1 , wherein said at least one marker is a chemokine.
10. The method according to claim 9 , wherein said chemokine is selected from the group consisting of CCL13 and XCL2.
11. The method of claim 1 , wherein said at least one marker is TRERF1 (SEQ ID NOs:1 and 2).
12. The method of claim 1 , wherein said at least one marker is C19orf28 (SEQ ID NOs: 3 and 4), CDKN1C (SEQ ID NOs: 5 and 6), SH3BP4 (SEQ ID NOs: 9 and 10), MTMR7 (SEQ ID NOs: 17 and 18), TMEFF1 (SEQ ID NOs: 19 and 20), NDUFA5 (SEQ ID NOs: 21 and 22), or FAT2 (SEQ ID NOs: 23 and 24).
13. The method of claim 1 , wherein the baseline sample is obtained from the subject prior to IVIG treatment.